Musculoskeletal

• Arthritis: Non‑erosive swelling of small joints (hands, wrists) or larger joints (knees, ankles). Usually symmetric.
• Myalgia: Muscle aches without true inflammation.
• Growth delay: Chronic inflammation and steroids can impair growth.

Renal (Kidney)

• Proteinuria: Presence of protein in urine; may be detected on routine dipstick.
• Hematuria: Blood in urine.
• Edema: Swelling of the ankles or face, especially in the morning.
• Hypertension: High blood pressure indicating lupus nephritis.

Neurological / Psychiatric

• Headache: Often severe or persistent.
• Seizures: May occur during active disease.
• Cognitive dysfunction: “Lupus fog,” difficulty concentrating.
• Mood disorders: Depression, anxiety, or psychosis.
• Peripheral neuropathy: Tingling or numbness.

Cardiovascular & Pulmonary

• Pleuritis: Sharp chest pain worsening with deep breaths.
• Pericarditis: Friction rub, chest discomfort.
• Myocarditis: Rare but serious inflammation of the heart muscle.
• Pulmonary hemorrhage: Coughing up blood—medical emergency.

Hematologic

• anemia (often normocytic, may be hemolytic)
• Leukopenia (low white‑blood‑cell count)
• Thrombocytopenia (low platelet count)
• Antiphospholipid antibodies leading to clotting abnormalities.

Other

• Hair loss (alopecia): Diffuse or patchy.
• Dry eyes/mouth (Sjogren‑like): May develop later.

Because symptoms can fluctuate, many children experience “flares” (periods of worsening disease) interspersed with remissions.

Causes and Risk Factors

JSLE, like adult SLE, is multifactorial—no single cause has been identified. The current model emphasizes an interplay of genetic susceptibility, environmental triggers, hormonal influences, and immune dysregulation.

Genetic Factors

• Family history of SLE or other autoimmune diseases raises risk (≈10‑15% of patients have a first‑degree relative with SLE).³
• Specific genes: HLA‑DR2, HLA‑DR3, and non‑HLA genes such as *IRF5*, *STAT4*, *PTPN22* increase susceptibility.

Environmental Triggers

• Ultraviolet (UV) light: Sun exposure can precipitate skin lesions and systemic flares.
• Infections: Epstein‑Barr virus, cytomegalovirus, and parvovirus B19 have been implicated as triggers.
• Medications: Certain drugs (e.g., procainamide, hydralazine) can induce a lupus‑like syndrome, though this is rare in children.

Hormonal Influence

• Estrogen appears to amplify immune responses, partly explaining the female predominance after puberty.

Other Risk Factors

• Ethnicity: Higher prevalence and more severe disease in African‑American, Hispanic, Asian, and Native American children.⁴
• Smoking exposure (including secondhand) may increase risk and flare severity.
• Low socioeconomic status is associated with delayed diagnosis and poorer outcomes.

Diagnosis

Diagnosing JSLE requires a combination of clinical evaluation, laboratory testing, and often imaging. Because many signs are nonspecific, pediatric rheumatologists use the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria, which assign weighted points to clinical and immunologic features. A total score ≥10 fulfills classification for SLE.

Key Laboratory Tests

• Antinuclear antibody (ANA): Positive in >95% of patients; screening test.
• Anti‑double‑stranded DNA (anti‑dsDNA) & anti‑Smith (anti‑Sm): Highly specific; levels often correlate with disease activity, especially renal involvement.
• Complement levels (C3, C4): Low complement suggests active consumption during flares.
• Complete blood count (CBC): Detects anemia, leukopenia, thrombocytopenia.
• Urinalysis & urine protein‑to‑creatinine ratio: Screens for lupus nephritis.
• Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, β2‑glycoprotein I): Assess clotting risk.

Imaging & Specialized Tests

• Echocardiogram: Evaluates pericardial effusion or valvular disease.
• Chest X‑ray or high‑resolution CT: Detects pleuritis, interstitial lung disease.
• Renal biopsy: Gold standard if significant proteinuria or declining kidney function; guides therapy.
• MRI of brain: Reserved for neurologic symptoms (e.g., seizures, focal deficits).

Differential Diagnosis

Conditions that can mimic JSLE include juvenile idiopathic arthritis, dermatomyositis, vasculitis, infections, and drug‑induced lupus. A thorough history, targeted exam, and systematic testing help distinguish these entities.

Treatment Options

Treatment aims to control inflammation, prevent organ damage, and minimize medication side effects. Because disease severity varies, therapy is individualized and often follows a “step‑up” approach.

First‑Line Medications

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): For mild joint pain and serositis (e.g., ibuprofen, naproxen). Use gastro‑protective agents as needed.
• Antimalarials – Hydroxychloroquine (HCQ): Cornerstone for all patients unless contraindicated; reduces flares, improves skin lesions, and may protect kidneys. Baseline and annual ophthalmologic exams are required.⁵
• Corticosteroids: Prednisone or methylprednisolone for rapid control of active disease. Low‑dose maintenance (<7.5 mg/day) is preferred to limit growth suppression, osteoporosis, and metabolic effects.

Immunosuppressive & Biologic Agents

• Azathioprine (AZA) or Mycophenolate Mofetil (MMF): First‑line steroid‑sparing agents for moderate disease and lupus nephritis.
• Cyclophosphamide: Intravenous pulses for severe, proliferative nephritis or neuro‑lupus; fertility counseling is essential.
• Calcineurin inhibitors (Tacrolimus, Cyclosporine): Helpful in refractory renal disease.
• Biologics:
  • Belimumab: Anti‑BLyS monoclonal antibody approved for pediatric SLE ≥5 years; reduces disease activity and steroid burden.
  • Rituximab:** Anti‑CD20 B‑cell depleting agent used off‑label for refractory cases (e.g., severe nephritis, neuro‑lupus).

Adjunctive Therapies

• Anticoagulation: Low‑dose aspirin or therapeutic anticoagulants for antiphospholipid syndrome.
• Vitamin D & Calcium: Counteract steroid‑induced bone loss; DEXA scanning every 2–3 years for high‑risk patients.
• Vaccinations: Non‑live vaccines (influenza, HPV, COVID‑19) are safe; avoid live vaccines while on high‑dose immunosuppression.

Lifestyle & Supportive Measures

• Sun protection: broad‑spectrum sunscreen SPF ≥ 30, protective clothing, and limiting peak‑hour exposure.
• Balanced diet rich in calcium, vitamin D, and antioxidants.
• Regular, low‑impact exercise (e.g., swimming, cycling) to maintain bone density and cardiovascular health.
• Psychological support: counseling, peer support groups, and school accommodations.

Living with Juvenile Systemic Lupus Erythematosus

JSLE is a chronic condition, but with modern therapy most children can lead active, productive lives. Below are practical tips for patients, families, and caretakers.

School & Social Life

• Develop an Individualized Education Plan (IEP) to allow for rest periods during flares.
• Communicate with teachers about medication schedules and potential side effects (e.g., photosensitivity).
• Encourage participation in activities the child enjoys, modifying intensity as needed.

Medication Adherence

• Use pill organizers or smartphone reminders.
• Explain the purpose of each drug in age‑appropriate language to foster ownership.
• Schedule regular pharmacy refill checks to avoid gaps.

Monitoring & Follow‑Up

• Routine visits every 3‑6 months or sooner during flares.
• Lab panel every visit: CBC, CMP, urinalysis, complement, anti‑dsDNA.
• Annual ophthalmology, dental, and bone‑density assessments when on HCQ or steroids.

Emotional Well‑Being

• Identify early signs of depression or anxiety; refer to mental‑health professionals.
• Encourage open discussions about body image, especially concerning hair loss or weight changes.
• Connect families with lupus foundations (e.g., Lupus Foundation of America) for resources and peer support.

Transition to Adult Care

Around ages 16‑18, begin a structured transition plan that includes a summary of disease history, medication list, and contact information for both pediatric and adult rheumatology teams.

Prevention

While JSLE cannot be prevented, certain strategies can reduce the likelihood of disease onset in high‑risk individuals and lower flare frequency in those already diagnosed.

• Sun avoidance: Daily sunscreen use and protective clothing.
• Smoking cessation: Both active and secondhand smoke increase autoimmunity.
• Infection control: Hand hygiene, timely vaccinations, and prompt treatment of infections.
• Stress management: Meditation, counseling, or yoga can mitigate stress‑related immune activation.
• Regular medical follow‑up: Early detection of lab abnormalities prevents irreversible organ damage.

Complications

If disease activity is not adequately controlled, JSLE can lead to serious, potentially life‑threatening complications.

• Lupus nephritis: Progressive kidney scarring leading to chronic kidney disease or end‑stage renal disease (ESRD). Approximately 30‑50% of children develop renal involvement.⁶
• Neuropsychiatric lupus: Seizures, psychosis, cognitive decline, or stroke.
• Cardiovascular disease: Accelerated atherosclerosis; increased risk of myocardial infarction in early adulthood.
• Infections: Immunosuppressive therapy predisposes to bacterial, viral, and opportunistic infections.
• Osteoporosis: Steroid use plus disease‑related inflammation can reduce bone mineral density.
• Pregnancy complications (in adolescents who become pregnant): Higher rates of preeclampsia, preterm birth, and fetal loss.
• Growth retardation & delayed puberty: Chronic inflammation and glucocorticoids impair growth hormone axis.

When to Seek Emergency Care

**References**

1. Petri M, et al. “Epidemiology of Pediatric Lupus: A Review.” Arthritis Care & Research. 2020.
2. U.S. Centers for Disease Control and Prevention. “Lupus Data Overview.” Updated 2022.
3. Hiraki LT, et al. “Genetics of Systemic Lupus Erythematosus.” Nature Reviews Rheumatology. 2021.
4. Kelley J, et al. “Racial and Ethnic Differences in Juvenile Lupus.” J Pediatr. 2019.
5. Mayo Clinic. “Hydroxychloroquine: Uses, Side Effects, and Dosing.” Accessed March 2024.
6. Alvarez J, et al. “Renal Outcomes in Juvenile Lupus Nephritis.” Kidney International. 2022.